An update on the pathology and clinical management of gouty arthritis

Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout

(2011) Robert T. Keenan et al.   AMERICAN JOURNAL OF MEDICINE

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

(2011) Robert L. Wortmann et al.   CLINICAL THERAPEUTICS

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

(2011)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

(2011) Naomi Schlesinger et al.   ARTHRITIS RESEARCH & THERAPY

The pathogenesis of bone erosions in gouty arthritis

(2010) N. Schlesinger et al.   ANNALS OF THE RHEUMATIC DISEASES

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

(2010) Robert A. Terkeltaub et al.   ARTHRITIS AND RHEUMATISM

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

(2010) Alexander So et al.   ARTHRITIS AND RHEUMATISM

Engagement of fatty acids with toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis

(2010) Leo A. B. Joosten et al.   ARTHRITIS AND RHEUMATISM

Canakinumab

(2010) Eugen Dhimolea   mAbs

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo

(2010) M. S. Hershfield et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anakinra's Efficacy is Variable in Refractory Gout: Report of Ten Cases

(2010) Kun Chen et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

(2010) Michael A Becker et al.   ARTHRITIS RESEARCH & THERAPY

Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis

(2009) R Torres et al.   ANNALS OF THE RHEUMATIC DISEASES

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

(2009) R Terkeltaub et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study

(2008) John S. Sundy et al.   ARTHRITIS AND RHEUMATISM

Resolution of gouty tophi after twelve weeks of pegloticase treatment

(2008) Herbert S. B. Baraf et al.   ARTHRITIS AND RHEUMATISM

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial

(2008) H. RALPH Schumacher et al.   ARTHRITIS AND RHEUMATISM

Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy

(2008) Michael A. Becker et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS